Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00027
|
|||||
| Drug Name |
Ganciclovir
|
|||||
| Synonyms |
2'-NDG; 2'-Nor-2'-deoxyguanosine; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BIOLF-62; BW 759; BW 759U; BW-759U; BW-795; BW-B 759U; Biolf 62; Citovirax; Cymevan; Cymeven; Cymevene; Cymevene (TN); Cytovene; Cytovene (TN); Cytovene-IV; DRG-0018; G 2536; GA2; GANCICLOVIR SODIUM; GCV; GCV & 1110U81; GCV & MSL; Ganciclovir & C34-dgA immunotoxin; Ganciclovir & D5-dgA immunotoxin; Ganciclovir (JAN/USP/INN); Ganciclovir [USAN:INN:BAN:JAN]; Ganciclovirum; Ganciclovirum [Latin]; Gancyclovir; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-and MSL, neutralizing monoclonal antibody; HHEMG; Hydroxyacyclovir; IN1478; MB3795; RS-21592; ST-605; Virgan; Vitrasert; Vitrasert (TN); Zirgan
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cytomegalovirus infections [ICD11: 1D82] | Approved | [1] | |||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H13N5O4
|
|||||
| Canonical SMILES |
C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
|
|||||
| InChI |
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
|
|||||
| InChIKey |
IRSCQMHQWWYFCW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 82410-32-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 255.23 | Topological Polar Surface Area | 135 | ||
| Heavy Atom Count | 18 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
-2.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321977
, 11111224
, 11111225
, 11466867
, 11467987
, 11486454
, 12013652
, 14749970
, 14798783
, 16217245
, 17405102
, 23929519
, 24278453
, 25622077
, 26758755
, 29222588
, 3720872
, 46507294
, 47216865
, 47515408
, 47589082
, 48185084
, 48185085
, 48334596
, 48404464
, 48404465
, 49681203
, 49698657
, 49974979
, 5006228
, 50106328
, 50106329
, 50113251
, 53777645
, 53800918
, 56312143
, 56312588
, 56424026
, 57321811
, 617697
, 7298558
, 76491727
, 7840003
, 7847399
, 7887702
, 7979369
, 81041223
, 8139883
, 85231063
, 866342
|
|||||
| ChEBI ID |
ChEBI:465284
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [4] | ||
| MATE2 | Transporter Info | Multidrug and toxin extrusion protein 2 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| MRP5 | Transporter Info | Multidrug resistance-associated protein 5 | Substrate | [6] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [7] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [8] | ||
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [7] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MATE1 | Transporter Info | Km = 5120 microM | Human embryonic kidney cells (HEK293)-MATE1 | [4] | |
| MATE2 | Transporter Info | Km = 4280 microM | Human embryonic kidney cells (HEK293)-MATE2K | [4] | ||
| OAT1 | Transporter Info | Km = 896 microM | Proximal tubule (S2) cells-OAT1 | [7] | ||
| OCT-1 | Transporter Info | Km = 516.2 microM | Proximal tubule (S2) cells-OCT1 | [7] | ||
| References | ||||||
| 1 | Valganciclovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64. | |||||
| 3 | Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501. | |||||
| 4 | Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. | |||||
| 5 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 6 | Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78. | |||||
| 7 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. | |||||
| 8 | FDA Drug Development and Drug Interactions | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.